Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411212 | 0.78 | — | — | |
| SCHEMBL124933 | 0.75 | PDPK1 (0.44) | LMNAMAPTHPGDKMT2AGAA | |
| SCHEMBL211528 | 0.75 | ALDH1A1 (0.44) | LMNAMAPTHPGDKMT2AGAA | |
| SCHEMBL7758682 | 0.75 | MEN1 (0.41) | LMNAMAPTKMT2AGAAMEN1 | |
| SCHEMBL1696135 | 0.75 | PSMD14 (0.36) | — | |
| SCHEMBL558291 | 0.75 | SMN1; SMN2 (0.44) | LMNAMAPTHPGDMAPK1KMT2A | |
| SCHEMBL6098342 | 0.75 | KDM4E (0.39) | LMNAPDE10AMAPTHPGDKMT2A | |
| SCHEMBL557619 | 0.75 | MAPT (0.37) | MAPT | |
| SCHEMBL558384 | 0.72 | MAPT (0.40) | LMNAMAPTKMT2AMEN1NPC1 | |
| SCHEMBL4337978 | 0.72 | LIMK1 (0.39) | HPGDMAPK1ALDH1A1CYP2A6MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493894-A1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | claimed |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |
| WO-2004072185-A1 | AZO METAL DYES AND OPTICAL DATA CARRIER CONTAINING ONE SUCH AZO METAL DYE AS A LIGHT ABSORBING COMPOUND IN THE INFORMATION LAYER | LANXESS DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| WO-2004072184-A1 | METAL COMPLEXES AS LIGHT-ABSORBING COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS | LANXESS DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| US-5681843-A | ANTIDIABETIC; ALDOSE REDUCTASE INHIBITOR WITHOUT SUBSTANTIALLY INHIBITING ALDEHYDE REDUCATASE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | claimed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | claimed |
| US-4978362-A | Thermoplastic resin composition containing polyalkyleneoxy-substituted azo coloring agents having trifluoromethyl substituents | MILLIKEN RESEARCH CORPORATION (US) | 1990-12-18 | — | — | US | claimed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | claimed |
| US-4751254-A | COLORING POLURETHANES USING POLYALKOXYTRIFLUOROANILINE COMPOUNDS | MILLIKEN RESEARCH CORPORATION (US) | 1988-06-14 | — | — | US | claimed |
| US-4578469-A | COUMARIN DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA2, CHRNA5 | PSMB8 1160/4885LMNA 2732/4885PDE10A 1207/4885 |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | PSMB8 3462/4885LMNA 1247/4885PDE10A 2876/4885 |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA6, CHRNA5 | PSMB8 2087/4885LMNA 2530/4885PDE10A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.